ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Drugs Outcomes Research and Policies
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1700175
This article is part of the Research TopicPharmacist and patient safety: Focus on drug safetyView all 9 articles
Low-dose Mivacurium Facilitates Laryngeal Mask Airway Insertion in Patients Undergoing Hysteroscopic Surgery: A Prospective, Single-center, Double-blind Randomized Controlled Trial
Provisionally accepted
Guan Yingchao
Lizhen WuHaochen WangConghui WangYusong LinMinghong JuXiaojing CongWen HeXiaodong Wang*- Weihai Municipal Hospital, Weihai, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: To explore whether the application of mivacurium can facilitate laryngeal mask airway (LMA) insertion and benefit patients. Methods: A total of 167 patients undergoing hysteroscopy were randomly divided into mivacurium (group M) and control (group C) groups. The anesthesia induction scheme was mivacurium+sufentanil+propofol in group M, whereas mivacurium was replaced with saline in group C. The main outcome was the LMA insertion condition Secondary outcomes included attempts and elapsed time of LMA insertion, intraoperative anesthetic consumption, perioperative hemodynamics, postoperative sore throat (POST), nausea, vomiting, dizziness, and agitation. Results: There was no difference in the baseline data (p>0.05). There was no significant difference in mouth opening; however, the incidence of swallowing, coughing, body movement, and pharyngeal spasm in group M was lower (p<0.001), and the proportion of no resistance during LMA insertion was higher (80.5% vs. 21.2%, p<0.001). The success rate of first-attempt LMA insertion in group M was higher (98.8% vs. 48.2%, p<0.001), the elapsed time was shorter (16.9(9.0) vs. 73.0(91.5) s, p<0.001), and fewer patients needed additional propofol (1.2% vs. 54.1%, p<0.001). Blood staining on the LMA surface showed no significant difference, but the postoperative pharyngeal pain score in group M was lower (1.0(1.0) vs. 2.0(1.0), p<0.001). Intraoperative propofol and remifentanil consumption, postoperative dizziness and nausea were lower in group M. Conclusions: Mivacurium facilitates LMA insertion and reduce intraoperative anesthetic consumption and adverse reactions, such as POST, nausea, and dizziness, so as to benefit the patient.
Keywords: Laryngeal mask airway, Mivacurium, Postoperative sore throat, Postoperative Nausea and Vomiting, randomized controlled trial
Received: 06 Sep 2025; Accepted: 07 Oct 2025.
Copyright: © 2025 Yingchao, Wu, Wang, Wang, Lin, Ju, Cong, He and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xiaodong Wang, wxd1982819@126.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.